Homology Medicines Inc represents values of innovation, integrity, and patient-centeredness. Their corporate philosophy revolves around developing groundbreaking genetic medicines to address serious rare diseases. Homology Medicines Inc is driven by a commitment to transform patients' lives by leveraging their proprietary platform technology, delivering precise, long-lasting genomic therapies. Their team of experts focuses on advancing gene therapy research and development, while upholding the highest standards of scientific excellence and ethical conduct. The company emphasizes collaboration with healthcare professionals, academia, and patient communities to ensure their therapies meet the unmet needs of patients worldwide.

Homology Medicines Inc is primarily present in the United States.

Some significant milestones achieved by Homology Medicines Inc include successful completion of Phase 1/2 pheNIX clinical trial for HMI-102 gene therapy in adults with phenylketonuria (PKU), initiation of Phase 1/2 pheNIX trial in pediatric PKU patients, and clearance of an Investigational New Drug (IND) application for HMI-103 gene therapy to treat metachromatic leukodystrophy (MLD). Furthermore, Homology Medicines has successfully developed an efficient and proprietary platform called AAVHSCs (adeno-associated virus vectors with human hematopoietic stem cells), which enables gene editing in hematopoietic stem cells. These achievements demonstrate the company's commitment to developing innovative gene therapies to address genetic diseases effectively, positioning Homology Medicines as a key player in the field.

Homology Medicines Inc is a biotechnology company focused on the development of genetic medicines. Established in 2015, Homology Medicines leverages its proprietary platform called AAVHSC (adeno-associated virus with homology-dependent DNA repair in mammalian cells) to treat rare genetic diseases. The company aims to provide transformative therapies for patients by harnessing the natural DNA repair process in the body. With a strong emphasis on gene editing and gene therapy technologies, Homology Medicines strives to address significant unmet medical needs. Through its research and development efforts, the company aims to pave the way for innovative genetic therapies that potentially offer long-term and durable solutions for patients in need.

The main competitors of Homology Medicines Inc in the market include companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.

Homology Medicines Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Homology Medicines Inc is focused on developing and commercializing genetic medicines for patients with rare genetic diseases. The company utilizes its proprietary platform technology, called AAVHSCs (adeno-associated virus vectors derived from human hematopoietic stem cells), to deliver genetic therapies to treat a wide range of disorders. Homology Medicines aims to bring innovative treatments to patients by leveraging its expertise in gene editing, gene therapy, and gene delivery. Through strategic partnerships and collaborations, the company aims to accelerate the development and delivery of potentially transformative medicines to address unmet medical needs in the rare disease community.

Коефициентът на цена спрямо печалбата (КЦП) на Homology Medicines е -2,08.

Коефициентът на цена към оборот (KUV) на Homology Medicines е 0.

AlleAktien качественият резултат за Homology Medicines е 1/10.

Приходите не могат да бъдат изчислени в момента за Homology Medicines.

очаквана Homology Medicines печалба е -66,10 млн. USD.

Homology Medicines Inc is a biopharmaceutical company focused on the development of gene therapies. The company's business model is based on the use of a proprietary gene therapy platform called AAVHSC (adeno-associated virus-human synthetic chromosome), which enables the transfer of genes to dissolve genetic diseases. The company operates in three main areas: research and development, production, and marketing. Homology's research and development arm focuses on the discovery and development of new gene therapies. The company has several programs in the pipeline that focus on various genetic diseases, including phenylketonuria (PKU) and metachromatic leukodystrophy (MLD). The goal is to develop a safe and effective treatment for patients with these diseases. Homology's production department includes the manufacturing of gene therapies using the AAVHSC technology, production of antibodies, and manufacturing of other biopharmaceutical products. The company has comprehensive production and manufacturing capacity to meet the demand for gene therapies. Homology's marketing department focuses on the marketing of gene therapies once they are approved. The company works closely with physicians, hospitals, and healthcare organizations to ensure that gene therapy is available to the right patients. The company also plans to develop offerings for the treatment of genetic diseases in collaboration with government agencies and healthcare providers. Homology differentiates itself from other gene therapy companies with its AAVHSC platform, which enables effective and safe gene therapy for a variety of genetic diseases. The platform also allows Homology to manufacture gene therapeutics for a larger patient population than other gene therapy companies. Additionally, Homology's broad range of products makes the company attractive to investors. Homology's gene therapies will operate in a rapidly growing industry as gene therapies prove useful for a variety of diseases. Furthermore, gene therapy appears to be a very profitable sector as the high costs of production and delivery of gene therapeutics provide a high return for companies. Due to its proprietary technology and broad product range, Homology has a strong position in the gene therapeutics market. Overall, Homology Medicines Inc's successful business model is based on its commitment to developing safe and effective gene therapies. The company is well-positioned to be successful in this growing sector and meet the needs of affected patients and their families.

Homology Medicines разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Homology Medicines в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Homology Medicines е US4380831077.

WKN на Homology Medicines е A2JGTY.

Тикерът на Homology Medicines е QTTB.

През последните 12 месеца Homology Medicines изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Homology Medicines да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Homology Medicines в момента е .

Homology Medicines изплаща дивидент на тримесечие. Той се разпределя в месеците .

Homology Medicines платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Homology Medicines се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Homology Medicines на 8.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 8.09.2024 г..

Последното дивидентно плащане беше извършено на 8.09.2024 г..

През година 2023 Homology Medicines изплати 0 USD под формата на дивиденти.

Дивидентите от Homology Medicines се изплащат в USD.